SCHEMBL30765751

SCHEMBL30765751

C[C@@H](Nc1nnc(-c2ccccc2F)n(CC(=O)NCc2cc3cnccc3[nH]2)c1=O)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
F3 P13726 4/20 0.34
F2 P00734 7/20 0.33
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33
PRSS3 P35030 1/20 0.33
LMNA P02545 1/20 0.32
MAPK1 P28482 3/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
ALDH1A1 P00352 2/20 0.31
GPR139 Q6DWJ6 1/20 0.31
KDM4E B2RXH2 1/20 0.31
HCRTR1 O43613 1/20 0.31
USP2 O75604 1/20 0.31
GAA P10253 1/20 0.31
TSHR P16473 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
TP53 P04637 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765753 0.90 F2 (0.34) F3F2PRSS1PRSS2PRSS3
SCHEMBL30765595 0.87 F3 (0.35) F3F2PRSS1PRSS2PRSS3
SCHEMBL30765829 0.85 F3 (0.34) F3F2PRSS1PRSS2PRSS3
SCHEMBL30765565 0.85 F3 (0.36) F3F2PRSS1PRSS2PRSS3
SCHEMBL30765440 0.84 F7 (0.39) F3F2PRSS1MAPK1
SCHEMBL30765439 0.84 F3 (0.35) F3F2PRSS1PRSS2PRSS3
SCHEMBL31558576 0.84 F3 (0.35) F3F2PRSS1PRSS2PRSS3
SCHEMBL30765885 0.84 MAPK1 (0.34) F3F2PRSS1PRSS2PRSS3
SCHEMBL30765945 0.83 F3 (0.34) F3F2PRSS1PRSS2PRSS3
SCHEMBL30765603 0.83 F2 (0.35) F3F2PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed